Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
Strictly Come Dancing host Claudia Winkleman asked the audience to "bear with me" as she prepares to make a return to the show this weekend.
Fears of Russian aggression have sparked training exercises in Poland designed to bolster NATO's presence in Eastern Europe.
At the end of a long day, the Prime Minister has revealed he swaps his policy briefcase for a vacuum cleaner to help out at home.